UCDCCC NCTN UG1 PROGRAM

项目总结/摘要 作为唯一一家为内陆北方加州约600万人提供的NCI指定癌症中心， 加州大学戴维斯分校综合癌症中心（UCDCCC）提供初级癌症护理， 人口不断增长，并作为该地区专科癌症护理的三级转诊中心。为此 申请作为NCTN网络领先的学术参与网站，由博士领导。大卫R甘达拉，医学博士，和 理查德K Valicenti，医学博士，UCDCCC将利用已经建立的多学科团队的癌症 来自内科肿瘤学、放射肿瘤学、外科专业、分子生物学/基因组学的研究人员， 病理学、放射学、生物统计学、护理和临床研究支持，以提供临床试验专业知识， 在广泛的肿瘤类型中的NCTN研究中的科学和行政领导和累积， 在NCTN集团网络中。UCDCCC和它的教师有一个长期的和证明的跟踪记录， 对NCI申办的临床试验活动以及NCI相关指导委员会做出有影响力的贡献 和倡议。预计UG 1的这一努力将扩大参与的范围和范围，包括 整合更多的研究人员，并为新教师和大三学生提供职业发展机会 investigators.凭借NCTN在转化和临床研究领导方面的良好记录， UCDCCC准备利用独特的机构优势，作为临床试验的实验室资源 并为假设驱动的临床研究做出贡献。 基于二十多年来已经作为临床试验“中心”，用于招募NCI申办的研究 在整个中北部加州，NCTN UG 1计划为UCDCCC创造了额外的机会， 既增加了主要研究中心的收益，又通过UCDCCC将NCTN试验的使用范围扩大到社区 癌症护理网络和附属网站，其中包括大量服务不足，农村和少数民族患者 人口。总之，UCDCCC代表了一个跨学科的组织和领导结构 与临床试验计划相关联，该计划将具有影响力，并确保NCTN试验的稳健增长。

PROJECT SUMMARY/ABSTRACT As the only NCI-designated cancer center for inland Northern California's approximately 6 million people, the UC Davis Comprehensive Cancer Center (UCDCCC) provides both primary cancer care to a large and growing population, and serves as the tertiary referral center for specialty cancer care for the region. For this application as a NCTN Network Lead Academic Participating Site, led by Drs. David R Gandara, MD, and Richard K Valicenti, MD, UCDCCC will leverage an already established multidisciplinary team of cancer investigators from medical oncology, radiation oncology, surgical specialties, molecular biology/genomics, pathology, radiology, biostatistics, nursing, and clinical research support to provide clinical trials expertise, scientific and administrative leadership and accrual in NCTN studies across a broad range of tumor types and throughout the NCTN group network. UCDCCC and its faculty have a long-standing and proven track record of impactful contribution to NCI-sponsored clinical trials activities, as well as to NCI-related steering committees and initiatives. This UG1 effort is anticipated to increase both the scope and reach of participation, including integrating additional researchers and providing career development opportunities for new faculty and junior investigators. With an already strong track record in translational and clinical research leadership for NCTN, UCDCCC is poised to exploit unique institutional strengths in serving as a laboratory resource for clinical trials and contributing to hypothesis-driven clinical research. Based on over two decades of already serving as the clinical trials “hub” for accrual to NCI-sponsored studies throughout North-Central California, this NCTN UG1 initiative creates a additional opportunities for UCDCCC to both increase main site accrual and to extend access to NCTN trials into the community through the UCDCCC Cancer Care Network and affiliate site, which includes substantial underserved, rural and minority patient populations. In summary, UCDCCC represents an interdisciplinary organizational and leadership structure linked to a clinical trials program that will be impactful and ensure robust accrual to NCTN trials.